Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree ® ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder.

Stephen V Faraone,Roberto Gomeni,Joseph T Hull,Gregory D Busse,Brendan Lujan,Jonathan Rubin,Azmi Nasser

Brain and behavior（2023）

引用 1|浏览9

暂无评分

摘要

Viloxazine ER significantly reduces the impairment of PR and SA in children and adolescents with ADHD. Although its effects on PR and SA are modest, many ADHD patients can be expected to achieve clinically meaningful improvements in PR and SA with viloxazine ER treatment for longer than 6 weeks.

查看译文

关键词

Qelbree® (viloxazine extended-release capsules),attention-deficit/hyperactivity disorder (ADHD),peer relations,social activities

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要